Smith & Nephew plc reported a revenue of $1,412 million for Q3 2024, marking a 4.0% increase from Q3 2023 ($1,357 million) despite challenges in China; the revenue for the full year is now expected to grow by around 4.5%. Key segments like Orthopaedics and Advanced Wound Management saw revenue increases of 2.3% and 6.5% respectively. The filing is categorized under Major Earnings Reports with a positive sentiment, indicating a significant event for investors.